Application for authorisation to place on the market MON 87427 × MON 89034 × MIR162 × NK603 maize in the European Union, according to Regulation (EC) No 1829/2003 on genetically modified food and feed

EFSA-GMO-NL-2016-131 / EFSA-Q-2016-00148

Part VII

Summary of Applications

1. GENERAL INFORMATION

1.1. Details of application

(a) Member State of application

The Netherlands

(b) Application number

Not available at the time of submission

(c) Name of the product (commercial and any other names)

The Monsanto development code for this genetically modified maize is MON 87427 \times MON 89034 \times MIR162 \times NK603. The commercial name that has been attributed to this product is TRECEPTA.

(d) Date of acknowledgement of valid application

Not available at the time of submission.

1.2. Applicant

(a) Name of applicant

Monsanto Company, represented by Monsanto Europe S.A.

(b) Address of applicant

Monsanto Europe S.A.

Avenue de Tervuren 270-272

B-1150 Brussels

BELGIUM

Monsanto Company

800 N. Lindbergh Boulevard

St. Louis, Missouri 63167

US

(c) Name and address of the representative of the applicant established in the Union (if the applicant is not established in the Union)

See above.

1.3. Scope of the application

(a) Genetically modified food

- ✓ Food containing or consisting of genetically modified plants
- Food produced from genetically modified plants or containing ingredients produced from genetically modified plants

(b) Genetically modified feed

- ☑ Feed containing or consisting of genetically modified plants
- ☑ Feed produced from genetically modified plants

(c) Genetically modified plants for food or feed uses

- Products other than food and feed containing of consisting of genetically modified plants with the exception of cultivation
- ☐ Seeds and plant propagating material for cultivation in the Union

The scope of this application covers the import, processing and all uses of MON 87427 \times MON 89034 \times MIR162 \times NK603, as any other maize but excluding cultivation. As maize is a segregating crop, the MON 87427 \times MON 89034 \times MIR162 \times NK603 grain segregates for all genes, including those introduced by genetic modification. The sub-combinations

Part VII - Summary – MON 87427 × MON 89034 × MIR162 × NK603 Completeness check #2 – May 2016

Monsanto Company 2

occur as segregating progeny in the harvested grains of MON 87427 \times MON 89034 \times MIR162 \times NK603. Therefore, the risk assessment of MON 87427 \times MON 89034 \times MIR162 \times NK603 should cover all combinations of the constituent events.

1.4. Is the product or the uses of the associated plant protection product(s) already authorised or subject to another authorisation procedure within the Union?

No ☑
Yes ☐ (in that case, specify)

1.5. Has the genetically modified plant been notified under Part B of Directive 2001/18/EC?

Yes \square

No ☑ (in that case, provide risk analysis data on the basis of the elements of Part B of Directive 2001/18/EC)

The risk assessment presented in the MON 87427 \times MON 89034 \times MIR162 \times NK603 application includes data collected from field trials conducted at multiple US locations covering a range of environmental conditions. A summary of the conclusions of the risk analysis that demonstrate the safety of MON 87427 \times MON 89034 \times MIR162 \times NK603 to humans, animals and the environment, has been presented in the respective sections throughout this summary.

1.6. Has the genetically modified plant or derived products been previously notified for marketing in the Union under Part C of Directive 2001/18/EC?

No 🗹

Yes \Box (in that case, specify)

1.7. Has the product been subject to an application and/or authorised in a third country either previously or simultaneously to this application?

No E

Yes \square in that case, specify the third country, the date of application and, where available, a copy of the risk assessment conclusions, the date of the authorisation and the scope of the application

Regulatory submissions have been made in the Canada, Colombia, Japan, Korea, Mexico, Taiwan and U.S. EPA.

Regulatory submissions will also be made to countries that import significant quantities of maize or food and feed products derived from maize and have functional regulatory review processes in place. Also, as appropriate, notifications will be made to countries that import significant quantities of maize and maize products and do not have a formal regulatory review process for biotechnology derived crops.

Until now, cultivation approval has been obtained in Canada.

1.8. General description of the product

(a) Name of the recipient or parental plant and the intended function of the genetic modification

MON $87427 \times MON 89034 \times MIR162 \times NK603$ is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding

Part VII - Summary – MON 87427 \times MON 89034 \times MIR162 \times NK603 Completeness check #2 – May 2016 Monsanto Company

methods. Therefore, this product inherited the traits as present in the parental lines, glyphosate-tolerance (from MON 87427 and NK603) and insect-protection (from MON 89034 and MIR162).

- Like MON 87427, MON 87427 × MON 89034 × MIR162 × NK603 expresses the CP4 EPSPS protein in vegetative and female reproductive tissue, conferring tolerance to glyphosate.
- Like MON 89034, MON 87427 × MON 89034 × MIR162 × NK603 expresses the Cry1A.105 and Cry2Ab2 proteins, conferring protection against certain lepidoperan insect pests.
- Like MIR162, MON 87427 × MON 89034 × MIR162 × NK603 expresses the Vip3Aa20 protein, conferring protection against certain lepidopteran insect pests and a phosphomannose isomerase (PMI) protein, which acts as a selectable marker.
- Like NK603, MON 87427 × MON 89034 × MIR162 × NK603 expresses the two CP4 EPSPS proteins (CP4 EPSPS and CP4 EPSPS L214P), conferring tolerance to glyphosate.
- (b) Types of products planned to be placed on the market according to the authorisation applied for and any specific form in which the product must not be placed on the market (such as seeds, cut-flowers, vegetative parts) as a proposed condition of the authorisation applied for

The scope of the current application is for authorization of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU for all uses according to Art 3 (1) and 15 (1) of Regulation (EC) No 1829/2003, with the exception of cultivation. The range of uses of this maize will be identical to the full range of equivalent uses of conventional maize.

(c) Intended use of the product and types of users

MON $87427 \times MON~89034 \times MIR162 \times NK603$ maize will be used and traded in the EU in the same manner as current commercial maize and by the same operators currently involved in the trade and use of maize.

(d) Any specific instructions and recommendations for use, storage and handling, including mandatory restrictions proposed as a condition of the authorisation applied for

MON 87427 × MON 89034 × MIR162 × NK603 is not different from conventional maize, except for its traits (glyphosate-tolerance and insect-protection). MON 87427 × MON 89034 × MIR162 × NK603 was shown to be as safe as conventional maize. Therefore, MON 87427 × MON 89034 × MIR162 × NK603 and derived products will be stored, packaged, transported, handeled and used in the same manner as curent commercial maize. No specific instructions and/or recommendations are considered necessary for the placing on the market of MON 87427 × MON 89034 × MIR162 × NK603 for import, processing and all uses in the EU, as specified in Section 1.8(b) of this document.

(e) If applicable, geographical areas within the Union to which the product is intended to be confined under the terms of the authorisation applied for

MON $87427 \times MON~89034 \times MIR162 \times NK603$ is suitable for use throughout the EU as any other maize. The scope of this application covers the import, processing and all uses of MON $87427 \times MON~89034 \times MIR162 \times NK603$, as any other maize but excluding cultivation.

(f) Any type of environment to which the product is unsuited

MON $87427 \times MON~89034 \times MIR162 \times NK603$ is suitable for use throughout the EU as any other maize. The scope of this application covers the import, processing and all uses of MON $87427 \times MON~89034 \times MIR162 \times NK603$ as any other maize but excluding cultivation.

(g) Any proposed packaging requirements

MON $87427 \times MON~89034 \times MIR162 \times NK603$ is not different from conventional maize, except for its traits (tolerance to glyphosate and protection against certain lepidopteran insect pests). Therefore, MON $87427 \times MON~89034 \times MIR162 \times NK603$ and derived products will be used in the same manner as other maize and no specific packaging is required.

(h) Any proposed labelling requirements in addition to those required by other applicable EU legislation than Regulation (EC) No 1829/2003 and when necessary a proposal for specific labelling in accordance with Article 13(2) and (3), Article 25(2)(c) and (d) and Article 25(3) of Regulation (EC) No 1829/2003. In the case of products other than food and feed containing or consisting of genetically modified plants, a proposal for labelling has which complies with the requirements of point A(8) of Annex IV to Directive 2001/18/EC must be included.

In accordance with Regulations (EC) No 1829/2003 and 1830/2003, a labelling threshold of 0.9 % is applied for the placing on the market of MON 87427 \times MON 89034 \times MIR162 \times NK603 and derived products.

Operators shall be required to label products containing or consisting of MON 87427 \times MON 89034 \times MIR162 \times NK603 with the words "genetically modified maize" or "contains genetically modified maize" and shall be required to declare the unique identifier in the list of GMOs that have been used to constitute the mixture that contains or consists of this GMO.

Operators shall be required to label foods and feeds derived from MON 87427 \times MON 89034 \times MIR162 \times NK603 with the words "produced from genetically modified maize". In the case of products for which no list of ingredients exists, operators shall ensure that an indication that the food or feed product is produced from GMOs is transmitted in writing to the operator receiving the product.

Operators handling or using MON 87427 \times MON 89034 \times MIR162 \times NK603 and derived foods and feeds in the EU shall be required to be aware of the legal obligations regarding traceability and labelling of these products. Given that explicit requirements for the traceability and labelling of GMOs and derived foods and feeds are laid down in Regulations (EC) No 1829/2003 and 1830/2003 and that authorised foods and feeds shall be entered in the EU Register for genetically modified food and feed, operators in the food/feed chain will be fully aware of the traceability and labelling requirements for MON 87427 \times MON 89034 \times MIR162 \times NK603. Therefore, no further specific measures are to be taken by the applicant.

(i) Estimated potential demand

(i) In the EU

There are no anticipated changes to the demand as a result of the introduction of MON $87427 \times MON 89034 \times MIR162 \times NK603$ into the maize supply. It is

anticipated that the introduction of MON 87427 \times MON 89034 \times MIR162 \times NK603 maize will replace some of the maize in exising food and feed products.

(ii) In EU export markets

There are no anticipated changes to the extent of maize production in exports markets as a result of the introduction of MON $87427 \times MON \ 89034 \times MIR162 \times NK603$ maize. It is anticipated that the introduction of MON $87427 \times MON \ 89034 \times MIR162 \times NK603$ maize will replace some of the maize grain products.

(j) Unique identifier in accordance with Regulation (EC) No 65/2004

The OECD unique identifier for MON $87427 \times MON$ $89034 \times MIR162 \times NK603$ is MON- $87427-7 \times MON-89Ø34-3 \times SYN-IR162-4 \times MON-ØØ6Ø3-6$.

The unique identifiers asigned to the sub-combinations are determined by combining MON-87427-7 and/or MON-89Ø34-3 and/or SYN-IR162-4 and/or MON-ØØ6Ø3-6 in any perceiveable way, excluding each separate single.

1.9. Measures suggested by the applicant to take in the case of unintended release or misuse of the product as well as measures for disposal and treatment

Because this application is for consent to import, process and all uses of MON 87427 \times MON 89034 × MIR162 × NK603 as any other maize, not including the cultivation in the EU, the only potential means of environmental release would be more likely to occur during import, storage and processing of MON 87427 × MON 89034 × MIR162 × NK603. However, modern methods of grain handling minimize losses of grain, so there is little chance of germination of spilt grain resulting in the development of mature plants of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU. Moreover, in the event of incidental spillage, the establishment of volunteer plants would be unlikely, since maize cannot survive without human assistance and is not capable of surviving as a weed. Although maize seed can over-winter in mild conditions and can germinate the following year, the appearance of maize in rotational fields is rare under European conditions. Maize volunteers, if they occur, are usualy killed by frost or could be easily controlled by the use of selective herbicides or by mechanical means. Moreover, the information presented in this application established that MON 87427 × MON 89034 × MIR162 × NK603 is not different in composition, nutritional and agronomic characteristics relative to the conventional counterpart, except for its tolerance to glyphosate and protection against certain lepidopteran insect pests, it is unlikely to pose any threat to the EU environment or to require special measures for its containment. Therefore, no special measures are considered to be required in case of misuse or unintended release, and no specific conditions are warranted or required for the placing on the market of MON 87427 \times MON 89034 × MIR162 × NK603 for import, processing and all uses as specified in Section 1.8(b).

2. Information relating to the recipient or (where appropriate) Parental Plants

2.1. Complete name

(a) Family name Poaceae (formerly Gramineae)

(b) Genus Zea

(c) Species mays (2n = 20)

(d) Subspecies N/A

(e) Cultivar/breeding line MON 87427, MON 89034, MIR162, NK603

(f) Common name Maize / Corn

2.2. Geographical distribution and cultivation of the plant, including the distribution within the Union

Maize is widely grown in the EU and represents a significant portion of global maize production. Significant areas of maize production in Europe include the Danube Basin from southwest Germany to the Black Sea along with southern France through the Po Valley of northern Italy.

From 2011 to 2015, the top maize grain producers were the United States (US), China, Brazil, the EU and Ukraine, accounting for 82% of average annual global maize production.

2.3. Information concerning reproduction (for environmental safety aspects)

(a) Mode(s) of reproduction

Maize is wind-pollinated, and the distances that viable pollen can travel depend on prevailing wind patterns, humidity, and temperature. Pollen is shed from the tassel and is viable for approximately 20 minutes to 24 hours depending on environmental conditions. Maize plants shed pollen for up to 14 days.

(b) Specific factors affecting reproduction

Maize, as a thoroughly domesticated plant, has lost all ability to disseminate its seeds and relies entirely on the aid of man for its distribution.

(c) Generation time

As maize is a short day plant, time to maturity is strongly influenced by photoperiod. Maize is an annual crop with cultural cycle ranging from as short as 60 to 70 days to as long as 43 to 48 weeks from grainling emergence to maturity.

2.4. Sexual compatibility with other cultivated or wild plant species (for environmental safety aspects)

Potential for cross-pollination with cultivated maize varieties

Maize morphology fosters cross-pollination; therefore, high levels of pollen mediated gene flow can occur in this species. Researchers recognize that (1) the amount of gene flow that occurs can be high because of open pollination; (2) the percent gene flow will vary by population, hybrid or inbred; (3) the level of gene flow decreases with greater distance between the source and recipient plants; (4) environmental factors affect the level of gene flow; (5) maize pollen is viable for a short period of time under field conditions; (6) maize produces ample pollen over an extended period of time; and, (7) maize is wind-pollinated;

pollinating insects, especially bees, are occasional visitors to the tassels but rarely visit silks of maize.

Potential for cross-pollination with wild species

Maize and annual teosinte (*Zea mays* subsp. *mexicana*), are genetically compatible, wind-pollinated and hybridize when in close proximity to each other *e.g.*, in areas of Mexico and Guatemala (Wilkes, 1972). There are no compatible wild relatives of maize in Europe.

In contrast with maize and teosinte, which hybridizes under certain conditions, it is only with extreme difficulty and special techniques that maize and the closely related perennial species, *Tripsacum* (gamma grass) hybridize. Furthermore, the offspring of the cross show varying levels of sterility and are genetically unstable.

Based on the above, the possibility of gene transfer between cultivated maize and annual teosinte or wild species of *Tripsacum* is highly unlikely.

2.5. Survivability (for environmental safety aspects)

(a) Ability to form structures for survival or dormancy

Although grown extensively throughout the world, maize is not considered a persistent weed or a plant that is difficult to control. Maize, as we know it today, cannot survive in the wild because the female inflorescence (the ear) is covered by a husk thereby restricting seed dispersal. The transformation from a wild, weedy species to one dependent on humans for its survival most likely evolved over a long period of time through plant breeding by the indigenous inhabitants of the Western Hemisphere.

(b) Specific factors affecting survivability

See Section 2.5.(a).

2.6. Dissemination (for environmental safety aspects)

(a) Ways and extent of dissemination

Maize is not listed as a weed in the major weed references (Crockett, 1977). In addition, maize has been grown throughout the world without any report that it is a serious weed. Modern maize does not survive as a weed because of past selection in the development of maize. During domestication of maize, traits often associated with weediness have been eliminated such as seed dormancy, a dispersal mechanism, and the ability to establish fertile populations outside of cultivation.

(b) Specific factors affecting dissemination

See Section 2.6.(a).

2.7. Geographical distribution within the Union of the sexually compatible species (for environmental safety aspects)

There are no sexually compatible wild relatives of maize in EU.

2.8. In the case of plant species not normally grown in the Union description of the natural habitat of the plant, including information on natural predators, parasites, competitors and symbionts (for environmental safety aspects)

Not applicable, as maize is grown in Europe.

2.9. Other potential interactions, relevant to the genetically modified plant, of the plant with organisms in the ecosystem where it is usually grown, or used elsewhere, including information on toxic effects on humans, animals and other organisms (for environmental safety aspects)

There are no known toxic effects of the maize plant to humans, animals or livestock; it has a history of safe use for human food and animal feed. Maize has been a staple of the human diet for centuries, and its processed fractions are consumed in a multitute of food and animal feed products. A thorough description of the anti-nutrients present in maize has been presented in an OECD consensus document.

3. MOLECULAR CHARACTERISATION

3.1. Information relating to the genetic modification

(a) Description of the methods used for the genetic modification

MON $87427 \times MON 89034 \times MIR162 \times NK603$ is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods. Genetic modification was used in the development of MON 87427, MON 89034, MIR162 and NK603. MON 87427, MON 89034 and MIR162 were developed through *Agrobacterium*-mediated transformation of maize tissues, whereas NK603 was developed by means of a particle acceleration method.

(b) Nature and source of the vector used

MON $87427 \times MON 89034 \times MIR162 \times NK603$ is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods and no vector has been used to produce this product.

(c) Source of donor nucleic acid(s) used for transformation, size and intended function of each constituent fragment of the region intended for insertion

MON 87427 \times MON 89034 \times MIR162 \times NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods and MON 87427 \times MON 89034 \times MIR162 \times NK603 inherited the inserted DNA fragments from the four parental lines.

3.2. Information relating to the genetically modified plant

- 3.2.1. Description of the trait(s) and characteristics which have been introduced or modified MON 87427 × MON 89034 × MIR162 × NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods and expresses:
 - two CP4 EPSPS proteins (CP4 EPSPS and CP4 EPSPS L214P¹) which are structurally and functionally equivalent and which impart tolerance to glyphosate;
 - the Cry1A.105, Cry2Ab2 and Vip3Aa20 proteins which provide protection from feeding damage caused by certain lepidopteran insect pests;
 - a phosphomannose isomerase (PMI) protein, which acts as a selectable marker by enabling transformed plant cells to utilize mannose as the only primary carbon source.

Part VII - Summary – MON 87427 \times MON 89034 \times MIR162 \times NK603 Completeness check #2 – May 2016 *Monsanto Company*

¹ Hereafter collectively referred to as the CP4 EPSPS proteins.

3.2.2. *Information on the nucleic acid(s) sequences actually inserted or deleted*

(a) The copy number of all detectable inserts, both complete and partial

The genome of MON 87427 \times MON 89034 \times MIR162 \times NK603 contains four different inserts, one inherited from each parental line. The sequence analyses on parental lines indicate that each of these contain a single copy of the T-DNA of interest at a single insertion site. The presence of these inserts in MON 87427 \times MON 89034 \times MIR162 \times NK603 was confirmed through sequence analysis.

(b) In case of deletion(s), size and function of the deleted region(s)

MON 87427 \times MON 89034 \times MIR162 \times NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods. Since the inserts present in MON 87427 \times MON 89034 \times MIR162 \times NK603 correspond to those of the parental lines, the characteristics of the insertions and the 5' and 3' flanking sequences should be conserved in this product.

(c) Sub-cellular location(s) of insert(s) (nucleus, chloroplasts, mitochondria, or maintained in a non-integrated form) and methods for its/their determination

These results from the sequence analysis confirmed the presence of the inserted sequences of MON 87427, MON 89034, MIR162 and NK603 and that no detectable rearrangements of these inserts occurred in MON 87427 × MON 89034 × MIR162 × NK603.

(d) The organisation of the inserted genetic material at the insertion site

Since the inserts present in MON $87427 \times MON~89034 \times MIR162 \times NK603$ correspond to those of the parental lines, the characteristics of the insertions and the 5' and 3' flanking sequences should be conserved in this product.

(e) In case of modifications other than insertion or deletion, describe function of the modified genetic material before and after the modification, as well as direct changes in expression of genes as a result of the modification

Not applicable.

3.2.3. Information on the expression of the insert

(a) Information on developmental expression of the insert during the life cycle of the plant

CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins expression levels were determined by a validated enzyme-linked immunosorbent assay (ELISA) in tissues collected from MON $87427 \times MON~89034 \times MIR162 \times NK603$. Forage and grain tissue samples of MON $87427 \times MON~89034 \times MIR162 \times NK603$ were collected from 4 replicate plots planted in a randomized complete block field design during the 2013 growing season from 5 field sites in the US (Table 1).

Table 1. Protein levels in MON $87427 \times MON 89034 \times MIR162 \times NK603 (\mu g/g dw)$

	CP4 EPSPS	Cry1A.105	Cry2Ab2	Vip3Aa20	PMI
Forage	300	32	29	100	4.4
Grain	13	2.4	0.69	59	1.4

(b) Parts of the plant where the insert is expressed

The expression of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins occurs throughout the plant at appropriate times of plant development. In terms of food and feed safety assessment of MON 87427 \times MON 89034 \times MIR162 \times NK603 forage and grain are the most relevant tissues.

3.2.4. Genetic stability of the insert and phenotypic stability of the genetically modified plant MON 87427 \times MON 89034 \times MIR162 \times NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods. Thereby, each parental line passes on its inserted DNA sequence to the resulting MON 87427 \times MON 89034 \times MIR162 \times NK603.

Sequence analyses demonstrate the presence of the inserted sequences of MON 87427 \times MON 89034 \times MIR162 \times NK603.

3.2.5. Information (for environmental safety aspects) on how the genetically modified plant differs from the recipient plant in:

(a) Mode(s) and/or rate of reproduction

Phenotypic and agronomic as well as environmental interaction data were collected from eight sites at field trials conducted in 2013 in major US maize growing regions. Randomized complete block design with four replicates at each field site was used. In each of the assessments MON 87427 × MON 89034 × MIR162 × NK603, either treated or not with glyphosate, was compared to an appropriate maize conventional counterpart (control) which has a genetic background similar to MON 87427 × MON 89034 × MIR162 × NK603 but does not possess the *cp4 epsps, cry1A.105, cry2Ab2, Vip3Aa20* or *pmi* expression cassettes. In addition, multiple conventional reference varieties were included to provide a range of comparative values that are representative of existing conventional reference varieties for each measured phenotypic, agronomic, and environmental interaction characteristic.

Results of this field study showed that there are no unexpected changes in the phenotype or ecological interactions indicative of increased pest or weed potential of MON $87427 \times MON 89034 \times MIR162 \times NK603$ compared to the conventional maize counterpart. These results concur with those obtained previously for MON 87427, MON 89034, MIR162 and NK603.

Based on the study described above, it is possible to conclude that no differences in the mode or rate of reproduction, dissemination, survivability or other agronomic, phenotypic or environmental interaction characteristics are expected in MON 87427 \times MON 89034 \times MIR162 \times NK603 and that MON 87427 \times MON 89034 \times MIR162 \times NK603 shows no difference to the conventional maize counterpart in its phenotypic and agronomic behaviour, except for its glyphosate-tolerance and insect-protection traits.

(b) Dissemination

See Section 3.2.5 (a).

(c) Survivability

See Section 3.2.5 (a).

(d) Other differences

See Section 3.2.5 (a).

3.2.6. Any change to the ability of the genetically modified plant to transfer genetic material to other organisms (for environmental safety aspects)

(a) Plant to bacteria gene transfer

None of the genetic elements in MON $87427 \times MON 89034 \times MIR162 \times NK603$ has a genetic transfer function. Therefore, no changes are expected in the ability of this maize to transfer genetic material to bacteria.

(b) Plant to plant gene transfer

Not applicable, the scope of the current application does not include the cultivation of MON $87427 \times MON 89034 \times MIR162 \times NK603$ varieties in the EU.

4. COMPARATIVE ANALYSIS

4.1. Choice of the conventional counterpart and additional comparators

MON $87427 \times MON~89034 \times MIR162 \times NK603$ was compared to LH244 \times LH287², a conventional maize counterpart with background genetics similar to MON $87427 \times MON~89034 \times MIR162 \times NK603$, as well as with other commercially available maize varieties.

4.2. Experimental design and statistical analysis of data from field trials for comparative analysis

MON 87427 × MON 89034 × MIR162 × NK603 maize and LH244 × LH287 were grown at eight field sites in major maize-growing areas of the US during the 2013 field season. Additionally, conventional reference varieties were included at each field sites to provide reference substances representative for their respective growing regions. At each field site, the test, the conventional counterpart and reference seeds were planted in a randomized complete block design with four replicates per block. Field sites were representative of commercial maize growing areas and were distributed to reflect a variety of agronomic practices, soils and climatic factors. Difference and equivalence tests were conducted using statistical models provided in EFSA guidance and according to the 2010 EFSA Scientific Opinion on Statistical considerations for the safety evaluation of GMOs.

4.3. Selection of material and compounds for analysis

The key nutrients and other nutritionally important components that were selected for analysis in the compositional studies were chosen on the basis of internationally accepted guidance provided by the OECD on compositional considerations for new varieties of maize.

Certain characteristics together with environmental interactions were studied to assess for a potential indicator of phenotypic changes.

4.4. Comparative analysis of agronomic and phenotypic characteristics

The assessment of the phenotypic, agronomic and environmental interactions of MON 87427 \times MON 89034 \times MIR162 \times NK603 compared to conventional maize demonstrated that there are no unexpected changes in the phenotype or ecological interactions indicative of increased plant weed or pest potential of MON 87427 \times MON 89034 \times MIR162 \times NK603 compared to LH244 \times LH287 (*see* also Section 3.2.5).

Part VII - Summary – MON 87427 \times MON 89034 \times MIR162 \times NK603 Completeness check #2 – May 2016 Monsanto Company

² LH244 × LH287 is referred to in the studies under the code name MPA640B.

4.5. Effect of processing

MON 87427 \times MON 89034 \times MIR162 \times NK603 has been shown not to be different from conventional maize, except for its glyphosate-tolerance and insect-protection traits. The processing of MON 87427 \times MON 89034 \times MIR162 \times NK603 is therefore not expected to be any different from that of conventional maize.

5. TOXICOLOGY

(a) Toxicological testing of newly expressed proteins

MON $87427 \times MON \, 89034 \times MIR162 \times NK603$ is not different from conventional maize except for the expression of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins. Therefore, the safety assessment of the newly expressed proteins is focused on the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins expressed in MON 87427 \times MON 89034 \times MIR162 \times NK603. The conclusion of safety to humans of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins was based upon the following considerations:

- The proteins have a demonstrated history of safe use;
- The proteins have no structural similarity to known toxins or other biologically active proteins that could cause adverse effects in humans or animals;
- The proteins are rapidly digested in mammalian digestive systems;

In addition, the low concentration of the proteins in tissues that are consumed provides additional assurance for their safety.

It is therefore possible to conclude that the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins are safe and pose no concerns for humans, animals and the environment.

(b) Testing of new constituents other than proteins

Maize has a long history of safe use and consumption around the world. The components analysed in MON $87427 \times MON~89034 \times MIR162 \times NK603$ were compositionally similar compared to conventional maize. Therefore, no testing of any constituent other than the introduced proteins is required.

(c) Information on natural food or feed constituents

Maize is known to contain a number of natural anti-nutritional analytes, such as phytic acid and raffinose. These anti-nutrients were evaluated in MON 87427 \times MON 89034 \times MIR162 \times NK603 compositional analyses and their levels were demonstrated to be comparable in MON 87427 \times MON 89034 \times MIR162 \times NK603 and in conventional maize. Therefore, the levels of food and feed constituents in MON 87427 \times MON 89034 \times MIR162 \times NK603 have not been altered.

(d) Testing of the whole genetically modified food and feed

The safety assessment demonstrates that MON $87427 \times MON \, 89034 \times MIR\, 162 \times NK603$ is as safe as conventional maize for food and feed use through the compositional assessment of MON $87427 \times MON \, 89034 \times MIR\, 162 \times NK603$ harvested forage and grain to harvested forage and grain from conventional maize already on the market. The safety for humans and animals of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins has been demonstrated on the basis of extensive characterization, history of safe use, lack of structural similarities with known protein toxins and allergens, absence of acute toxicity in oral gavage studies in rodents and rapid digestion in simulated digestive fluids.

Moreover, the history of safe use of the introduced proteins and the familiarity of the host organisms from which the genes are derived have been demonstrated.

Based on this weight of evidence, no more data is required to demonstrate that MON 87427 \times MON 89034 \times MIR162 \times NK603 is as as safe as conventional maize from a food and feed perspective and therefore it can be concluded that there was no evidence of any adverse effects on human or animal health.

6. ALLERGENICITY

(a) Assessment of allergenicity of the newly expressed protein

Following the guidelines adopted by the Codex Alimentarius Commission, an assessment of potential allergenicity of introduced proteins has been conducted. This assessment demonstrated that it is unlikely that the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins will cause allergenic concerns due to the following considerations:

- The proteins were obtained from a non-allergenic source;
- The proteins lack structural similarity to known allergens, as demonstrated by bioinformatic analyses;
- The proteins are rapidly digested by pepsin, a key enzyme in the mammalian gastrointestinal system.

In addition, the CP4 EPSPS, CrylA.105, Cry2Ab2, Vip3Aa20 and PMI proteins comprise a very small portion of the total protein present in the grain of MON $87427 \times MON 89034 \times MIR162 \times NK603$.

Based on a weight of evidence, it can be concluded that the allergenic potential of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins is negligible and therefore, the proteins do not pose a significant allergenic risk.

(b) Assessment of allergenicity of the whole genetically modified plant

MON 87427 \times MON 89034 \times MIR162 \times NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods. Therefore, this product inherited the traits as present in the parental lines. The assessment of a potential allergenicity of each of the parental lines against a conventional maize has been previously performed. Results of these assessments support the conclusion that both MON 87427 \times MON 89034 \times MIR162 \times NK603 are comparable to conventional maize in terms of allergenicity potential.

As the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins expressed in MON $87427 \times MON~89034 \times MIR162 \times NK603$ are not allergenic and as there are no new genetic modifications in MON $87427 \times MON~89034 \times MIR162 \times NK603$, there are no reasons to believe that the expression of these proteins in MON $87427 \times MON~89034 \times MIR162 \times NK603$ would alter its endogenous allergen content compared to commercial maize.

7. NUTRITIONAL ASSESSMENT

(a) Nutritional assessment of the genetically modified food

The inherited traits in MON $87427 \times MON 89034 \times MIR162 \times NK603$ are of agronomic interest and are not intended to change any nutritional aspect of this maize. The presence of these traits is not expected to alter patterns or volumes of maize consumption. Results of

the extensive compositional analyses indicate that observed differences fell within the range of natural variability for maize with a history of safe usage and the forage and grain composition of MON 87427 × MON 89034 × MIR162 × NK603 is not biologically relevantly different to the forage and grain composition of the conventional counterpart, except for the expression of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins.

MON 87427 \times MON 89034 \times MIR162 \times NK603 shows comparable nutritional characteristics to the conventional maize counterpart, as well as to conventional maize varieties. Hence this maize is not expected to be more or less attractive for use as food (or feed), for processing or as a food (or feed) ingredient. Therefore, anticipated dietary intake of maize-derived foods (and feeds) is not expected to be altered and no nutritional imbalances are expected as a result of the presence of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the maize supply.

(b) Nutritional assessment of the genetically modified feed *See* Section 7 (a).

8. EXPOSURE ASSESSMENT – ANTICIPATED INTAKE/EXTENT OF USE

The exposure assessment in humans and animals indicates that there is minimal dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins from consumption of foods and feed derived from MON 87427 × MON 89034 × MIR162 × NK603.

There are no anticipated changes in the intake and/or extent of use of maize or derived products for use as or in food or feed as a result of the addition of MON $87427 \times MON \ 89034 \times MIR162 \times NK603$ to the maize supply. MON $87427 \times MON \ 89034 \times MIR162 \times NK603$ is expected to replace a portion of current maize such that its intake or use will represent some fraction of the total products derived from maize.

9. RISK CHARACTERISATION

Based on the information provided in this application, it can be concluded that MON 87427 \times MON 89034 × MIR162 × NK603 is as safe as conventional maize. The molecular characterization of MON 87427 × MON 89034 × MIR162 × NK603 did not raise any safety concern and did not show any evidence of unintended changes in MON 87427 × MON 89034 × MIR162 × NK603. Detailed compositional comparisons of MON 87427 × MON 89034 × MIR162 × NK603, its conventional counterpart and conventional reference varieties demonstrated that MON 87427 × MON 89034 × MIR162 × NK603 is compositionally similar to the conventional maize counterpart and that MON 87427 × MON 89034 × MIR162 × NK603 is not a contributor to compositional variability in maize. The assessed phenotypic and agronomic characteristics of MON 87427 × MON 89034 × MIR162 × NK603 were within the range expected for maize and did not show any phenotypic changes indicative of increased plant weed/pest potential of MON 87427 × MON 89034 × MIR162 × NK603 compared to conventional maize. An extensive characterisation of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins expressed in MON 87427 × MON 89034 × MIR162 × NK603 confirmed that these proteins are safe for human and animal consumption. Additionally, the exposure assessment in humans and animals did not indicate any safety concerns.

In summary, there are no signs of adverse or unanticipated effects observed in a number of safety studies and the pre-market risk characterisation for food and feed use of MON $87427 \times MON 89034 \times MIR162 \times NK603$. The consumption of food and feed derived from MON 87427

 \times MON 89034 \times MIR162 \times NK603 is as safe as the consumption of its conventional counterpart. It can be concluded that the food derived from MON 87427 \times MON 89034 \times MIR162 \times NK603 is not nutritionally disadvantageous for the consumer compared to the food which is intended to replace. Finally, it can be also concluded that the feed derived from MON 87427 \times MON 89034 \times MIR162 \times NK603does not harm or mislead the consumer by impairing distinctive features of the animal products compared to conventionally produced feed.

Based on the molecular characterisation, expression of the inherited genes, outcomes of the comparative analysis of compositional, phenotypic and agronomic characteristics of maize MON $87427 \times MON$ $89034 \times MIR162 \times NK603$, the known functional characteristics and modes of action of the newly expressed proteins, it is unlikely that the sub-combinations of its constituent single events have an adverse effect on human and animal health and the environment, in the context of their intended uses, which cover food and feed uses, import and processing.

10. POST-MARKET MONITORING ON THE GENETICALLY MODIFIED FOOD OR FEED

As demonstrated in this application, there are no intrinsic hazards related to MON 87427 \times MON 89034 \times MIR162 \times NK603. No data have emerged to indicate that MON 87427 \times MON 89034 \times MIR162 \times NK603 is less safe than its conventional counterpart. The pre-market risk characterisation for food and feed use of MON 87427 \times MON 89034 \times MIR162 \times NK603 demonstrates that the risks of consumption of MON 87427 \times MON 89034 \times MIR162 \times NK603 or its derived products are no different from the risks associated with the consumption of conventional maize and maize-derived products. As a consequence, specific risk management measures are not indicated and post-market monitoring of the use of this maize for food and feed is not considered necessary.

11. ENVIRONMENTAL ASSESSMENT

11.1. Mechanism of interaction between the genetically modified plant and target organisms

According to the EFSA ERA Guidance, the primary focus for the assessment on target organisms is the development of resistance to the insect or pathogen tolerance traits expressed by the GM plant (EFSA, 2010).

The scope of this application covers the import, processing and all uses as any other maize, but excludes the cultivation of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the EU. Therefore, the likelihood is negligible that the import of MON 87427 \times MON 89034 \times MIR162 \times NK603 will result in plants of this maize being present in the environment, and the potential for interactions between MON 87427 \times MON 89034 \times MIR162 \times NK603 and its target organisms is, therefore, considered to be minimal if existing at all. As a consequence, an assessment of the potential resistance development in target organisms resulting from import, processing and all uses as any other maize, but excluding the cultivation of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the EU is not relevant for this submission.

11.2. Potential changes in the interactions of the genetically modified plant with the biotic environment resulting from the genetic modification

The scope of this application covers the import, processing and all uses as any other maize, but excluding the cultivation of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU. Therefore, no deliberate release of viable plant material in the EU environment is expected, and

interactions of MON $87427 \times$ MON $89034 \times$ MIR162 \times NK603 with the biotic environment will be limited.

(a) Persistence and invasiveness

Results from the assessment support the conclusion that the abilities of MON 87427 \times MON 89034 \times MIR162 \times NK603 to persist in agricultural fields or invade non-agricultural habitats are comparable to those of conventional maize in the EU. Thus, MON 87427 \times MON 89034 \times MIR162 \times NK603 is not more likely to represent an agronomic problem in agricultural fields or become more invasive in natural habitats and no adverse effects on ecological functions within agricultural production fields or on biodiversity is expected as a result of the import, processing and all uses as any other maize.

(b) Selective advantage or disadvantage

Compared with conventional maize, the introduced glyphosate-tolerance and insect-protection traits in MON 87427 \times MON 89034 \times MIR162 \times NK603 confer a selective advantage only under specific conditions (*i.e.* following treatment with glyphosate or upon attack by the target insects), which are short in duration. The advantage is of purely agronomic interest and presents negligible risk to the non-agricultural environments, because of the poor survival characteristics of maize under most European conditions.

Therefore, the likelihood is negligible for the inherited traits in MON $87427 \times MON 89034 \times MIR162 \times NK603$ to confer any meaningful competitive advantage or disadvantage of relevance to the environment.

(c) Potential for gene transfer

Given the low likelihood of occurrence of horizontal gene transfer and lack of adverse consequences if it were to occur, the import, processing, and food and feed use of MON $87427 \times MON~89034 \times MIR162 \times NK603$ in the EU is not likely to adversely impact human, animal, or environmental health, and poses negligible risk.

(d) Interactions between the genetically modified plant and target organisms

An assessment of the potential resistance development in target organisms resulting from the import, processing and all uses as any other maize of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU is not relevant for this application.

(e) Interactions of the genetically modified plant with non-target organisms

Given the low levels of environmental exposure combined with low hazard from exposure of MON 87427 \times MON 89034 \times MIR162 \times NK603 to non-target organisms (NTOs), the likelihood of adverse effects to NTO communities that perform in-field ecological functions and NTO communities outside of the field from import of MON 87427 \times MON 89034 \times MIR162 \times NK603, is negligible.

(f) Effects on human health

Given the low levels of environmental exposure combined with the negligible hazard occurring from the contact with MON $87427 \times MON~89034 \times MIR162 \times NK603$ grain, the likelihood for any adverse effects on humans and animals handling MON $87427 \times MON~89034 \times MIR162 \times NK603$ import and processing in the EU is negligible.

(g) Effects on animal health

See Section 11.2.(f).

(h) Effects on biogeochemical processes

Given the low level of environmental exposure combined with a lack of hazard, the import, processing and all uses of MON $87427 \times MON~89034 \times MIR162 \times NK603$ as any other maize in the EU is not likely to adversely impact soil micro-organisms that perform ecological functions in-field or in non-agricultural habitats, and therefore poses negligible environmental risk.

(i) Impacts of the specific cultivation, management and harvesting techniques

Cultivation of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the EU is not included in the scope of this application. An assessment of the impacts of specific cultivation, management and harvesting techniques of MON 87427 \times MON 89034 \times MIR162 \times NK603 is therefore not relevant for this application.

11.3. Potential interactions with the abiotic environment

MON 87427 \times MON 89034 \times MIR162 \times NK603 carries two traits of agronomic interest: glyphosate-tolerance and insect-protection. As MON 87427 \times MON 89034 \times MIR162 \times NK603 was shown not to be different from conventional maize (with the exception of the inherited traits, imparted by the expression of the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins), with respect to its composition and agronomic and phenotypic characteristics, there is no evidence that this maize would be any different from conventional maize with regard to its baseline interactions with the abiotic environment.

Although the CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins are introduced in maize, they already have a safe history of use and they have no known negative interactions with the abiotic environment.

In addition, because this application is for import, processing and all uses as any other maize in the EU, but excluding cultivation, interactions of MON 87427 \times MON 89034 \times MIR162 \times NK603 with the environment will be limited. Moreover, no negative impact of MON 87427 \times MON 89034 \times MIR162 \times NK603 on the abiotic environment is expected to result from the import, processing and all uses as any other maize in the EU.

11.4. Risk characterization

Results from the environmental risk assessment which takes into consideration the risk characterization and includes results described above addressing risk hypotheses for the specific areas of assessment laid down in EFSA (2010)guidance, support a conclusion that the import, processing and all uses in the EU (excluding cultivation) of MON 87427 \times MON 89034 \times MIR162 \times NK603, as any other maize, represents negligible risk to human and animal health and the environment, and poses no greater risk than the import and processing of conventional maize. Because no immediate adverse effects are expected, the probability of long-term adverse effects is also negligible. Based on the conclusions formulated for MON 87427 \times MON 89034 \times MIR162 \times NK603 and maize being a segregant crop, there is no reason to expect that any subcombination of the single events would represent a risk to human and animal health or the environment.

12. ENVIRONMENTAL MONITORING PLAN

(a) General (risk assessment, background information)

As required by Article 5(5)(b) and 17(5)(b) of Regulation (EC) No 1829/2003 the proposed monitoring plan for MON $87427 \times MON$ $89034 \times MIR162 \times NK603$ has been developed according to the principles and objectives outlined in Annex VII of Directive 2001/18/EC

and Decision 2002/811/EC establishing guidance notes supplementing Annex VII to Directive 2001/18/EC. The monitoring plan also takes into account the EFSA Scientific Opinion on guidance on the Post-Market Environmental Monitoring (PMEM) of genetically modified plants (EFSA, 2011).

(b) Interplay between environmental risk assessment and monitoring

The scope of this application is the authorization of MON $87427 \times MON 89034 \times MIR162 \times NK603$ for import, processing and all uses as any other maize in the EU under Regulation (EC) No 1829/2003. The scope of the application does not include authorization for the cultivation of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU.

An environmental risk assessment (ERA) was carried out for MON 87427 \times MON 89034 \times MIR162 \times NK603 according to the principles laid down in Annex II to Directive 2001/18/EC, Decision 2002/623/EC establishing guidance notes supplementing Annex II to Directive 2001/18/EC and the EFSA guidance on the environmental risk assessment of genetically modified plants. The scientific evaluation of the characteristics of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the ERA has shown that the risk for potential adverse effects on human and animal health or the environment is negligible in the context of the intended uses of MON 87427 \times MON 89034 \times MIR162 \times NK603 relative to:

- Persistence and invasiveness including plant-to-pant gene flow
- Plant to micro-organims gene transfer
- Interactions of the GM plant with target organisms
- Interactions of the GM plant with non-target organisms (NTOs)
- Impacts of the specific cultivation, management and harvesting techniques
- Effects on biogeochemical processes
- Effects on human and animal health

(c) Case-specific genetically modified plant monitoring (approach, strategy, method and analysis)

The scientific evaluation of the characteristics of MON 87427 \times MON 89034 \times MIR162 \times NK603 in the ERA has shown that the risk for potential adverse effects on human and animal health or the environment is negligible in the context of the intended uses of MON 87427 \times MON 89034 \times MIR162 \times NK603. It is therefore considered that there is no need for case-specific monitoring.

(d) General surveillance of the impact of the genetically modified plant (approach, strategy, method and analysis)

Any potential adverse effects of MON 87427 × MON 89034 × MIR162 × NK603 on human health and the environment, which were not anticipated in the ERA, can be addressed under the general surveillance. General surveillance is largely based on routine observation and implies the collection, scientific evaluation and reporting of reliable scientific evidence, in order to be able to identify whether unanticipated, direct or indirect, immediate or delayed adverse effects have been caused by the placing on the market of a genetically modified (GM) crop in its receiving environment.

In order to allow detection of the broadest possible scope of unanticipated adverse effects, general surveillance is performed by either selected, existing networks, or by specific company stewardship programmes, or by a combination of both. The consent holder will ensure that appropriate technical information on MON $87427 \times MON 89034 \times MIR162 \times MIR1$

NK603 and relevant legislation will be available for the relevant networks, in addition to further relevant information from a number of sources, including industry and government websites, official registers and government publications.

Following the approval of this maize in the EU, the consent holder will approach key stakeholders and key networks of stakeholders of the product (including international grain traders, maize processors and users of maize grain for animal feed) and inform them that the product has been authorised. The consent holder will request key stakeholders and networks for their participation in the general surveillance of the placing on the market of this maize, in accordance with the provisions of Directive 2001/18/EC and the consent. Key stakeholders and networks will be requested to be aware of their use of this maize and to inform the consent holder in case of potential occurrence of any unanticipated adverse effects to health or the environment, which they might attribute to the import or use of this product. Appropriate technical information on MON 87427 × MON 89034 × MIR162 × NK603 will be provided to them.

Where there is scientifically valid evidence of a potential adverse effect (whether direct or indirect), linked to the genetic modification, then further evaluation of the consequence of that effect should be science-based and compared with available baseline information. Relevant baseline information will reflect prevalent use practices and the associated impact of these practices on the environment. Where scientific evaluation of the observation confirms the possibility of an unanticipated adverse effect, this would be investigated further to establish a correlation, if present, between the use of MON 87427 × MON 89034 × MIR162 × NK603 and the observed effect. The evaluation should consider the consequence of the observed effect and remedial action, if necessary, should be proportionate to the significance of the observed effect.

(e) Reporting the results of monitoring

In accordance with Regulation (EC) No 1829/2003, the authorisation holder is responsible to inform the European Commission of the results of the general surveillance.

If information that confirms an adverse effect of MON $87427 \times MON 89034 \times MIR162 \times NK603$ and that alters the existing risk assessment becomes available, the authorisation holder will immediately investigate and inform the European Commission. The authorisation holder, in collaboration with the European Commission and based on a scientific evaluation of the potential consequences of the observed adverse effect, will define and implement management measures to protect human and animal health or the environment, as necessary. It is important that the remedial action is proportionate to the significance of the observed effect.

The authorization holder will submit an annual monitoring report including results of the general surveillance in accordance with the conditions of the authorization. The report will contain information on any unanticipated adverse effects that have arisen from handling and use of viable MON $87427 \times MON 89034 \times MIR162 \times NK603$.

The report will include a scientific evaluation of the confirmed adverse effect, a conclusion of the safety of MON $87427 \times MON~89034 \times MIR162 \times NK603$ and, as appropriate, the measures that were taken to ensure the safety of human and animal health or the environment.

The report will also clearly state which parts of the provided information are considered to be confidential, together with a verifiable justification for confidentiality in accordance with Article 30.

13. DETECTION AND EVENT-SPECIFIC IDENTIFICATION TECHNIQUES FOR THE GENETICALLY MODIFIED PLANT

As MON 87427 \times MON 89034 \times MIR162 \times NK603 is produced by crossing maize plants containing MON 87427, MON 89034, MIR162 and NK603 using traditional breeding methods, it contains all four inserts in combination. Therefore, MON 87427 \times MON 89034 \times MIR162 \times NK603 is detectable using either the event-specific PCR method for detecting the introduced DNA present in MON 87427, MON 89034, MIR162 or NK603. However, as for all plants in which one or more events are combined by traditional breeding, the unambiguous detection of MON 87427 \times MON 89034 \times MIR162 \times NK603 in mixed consignments of seed will require single maize seeds to be subjected to detection methods for MON 87427 \times MON 89034 \times MIR162 \times NK603, and to test positive for all.

- 14. Information Relating To Previous Releases Of The Genetically modified Plant (for environmental safety aspects)
- 14.1. History of previous releases of the genetically modified plant notified under Part B of Directive 2001/18/EC or under Part B of Directive 90/220/EEC by the same notifier
 - (a) Notification number

There is no history of release of MON $87427 \times MON 89034 \times MIR162 \times NK603$ in the EU.

(b) Conclusions of post-release monitoring

Not applicable

(c) Results of the release in respect to any risk to human health and the environment, submitted to the competent authority according to Article 10 of Directive 2001/18/EC)

Not applicable

- 14.2. History of previous releases of the genetically modified plant carried out outside the Union by the same notifier
 - (a) Release country

MON 87427 \times MON 89034 \times MIR162 \times NK603 has been field tested in the US since 2013.

(b) Authority overseeing the release

US and Puerto Rico: United States Environmental Protection Agency (U.S. EPA)

(c) Release site

US: In major corn growing region.

(d) Aim of the release

US: Regulatory, efficacy, yield, breeding, product development, and demonstration trials.

(e) Duration of the release

US: One growing season.

(f) Aim of post-releases monitoring

US: Assessment of volunteers.

(g) Duration of post-releases monitoring

US: 12 months.

(h) Conclusions of post-release monitoring

US: In general, no volunteers have been observed since maize is an annual crop. If volunteers occur, practice is to eliminate them manually or chemically to prevent occurrence in subsequent crops.

(i) Results of the release with respect to any risk to human health and the

Field-testing provided no evidence that MON $87427 \times MON 89034 \times MIR162 \times NK603$ or derived products would be the cause of any adverse effects to human health or to the environment.

REFERENCES

- Crockett L, 1977. Wildly successful plants: North American Weeds. University of Hawaii Press, 1-4.
- EFSA, 2010. Guidance on the environmental risk assessment of genetically modified plants. The EFSA Journal, 8(11):1879, 1-111.
- EFSA, 2011. Guidance on the post-market environmental monitoring (PMEM) of genetically modified plants. The EFSA Journal, 9 (8), 1-40.
- Wilkes HG, 1972. Maize and its wild relatives. Science, 177, 1071-1077.